Quantitative measurement of cell-free plasma DNA and applications for detecting tumor genetic variation and promoter methylation in a clinical setting

Journal of Molecular Diagnostics

Volumn 14, Issue 4, 2012, Pages 346-356

  Kadam, Sunil K ^a   Farmen, Mark ^a   Brandt, John T ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CELL FREE DNA; CYCLIN D2; PROTEIN P16; PROTEIN P53; SECRETED FRIZZLED RELATED PROTEIN 1; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER GENETICS; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; DISEASE MARKER; DNA DETERMINATION; DNA EXTRACTION; DNA ISOLATION; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PROMOTER REGION; QUANTITATIVE GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR BIOPSY;

DNA; DNA METHYLATION; GENETIC VARIATION; HUMANS; PROMOTER REGIONS, GENETIC;

EID: 84862670402     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2012.03.001     Document Type: Article

References (49)

1. Bendich A, Wilczok T, Borenfreund E: Circulating DNA as a possible factor in oncogenesis. Science 1965, 148:374-376
2. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650
3. Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN Jr., Lu C, Gershenson DM, Simpson JL, Sood AK: Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 2006, 5:1369-1374
4. Behera D, Gumbhir K, Malik SK, Dani HM: Lung cancer and circulating DNA. Indian J Chest Dis Allied Sci 1986, 28:54-55
5. Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18:65-73
6. Theodor L, Melzer E, Sologov M, Idelman G, Friedman E, Bar-Meir S: Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum. Dig Dis Sci 1999, 44:2014-2019
7. Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T, Oka M: Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006, 26:4713-4719
8. Musacchio JG, Carvalho Mda G, Morais JC, Silva NH, Scheliga A, Romano S, Spector N: Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease. Sao Paulo Med J 2006, 124:154-157
9. van der Vaart M, Pretorius PJ: Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 2008, 1137:18-26
10. Marchese R, Muleti A, Brozzetti S, Gandini O, Brunetti E, French D: Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer. Br J Cancer 2004, 90:2243
11. Haihua Y, Zhonh-Zeng Z, Yachao L, Feng L, Wenying Z, Gang H, Guanshan Z, Jiang B: A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis. Yonsei Med J 2012, 53:132-137
12. Danese E, Montagnana M, Minicozzi AM, De Matteis G, Scudo G, Salvagno GL, Cordiano C, Lippi G, Guidi GC. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med 2010, 48:1665-1668
13. García-Olmo DC, Domínguez C, García-Arranz M, Anker P, Stroun M, García-Verdugo JM, García-Olmo D: Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res 2010, 70:560-567
14. Xue X, Zhu YM, Woll PJ: Circulating DNA and lung cancer. Ann N Y Acad Sci 2006, 1075:154-164
15. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M: Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005, 65:1141-1145
16. Fujimoto A, O'Day SJ, Taback B, Elashoff D, Hoon DS: Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res 2004, 64:4085-4088
17. van der Vaart M, Pretorius PJ: Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 2010, 43:26-36
18. Gormally E, Caboux E, Vineis P, Hainaut P: Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007, 635:105-117
19. Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P, Pastorino U. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 2005, 97:1848-1850
20. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques. 1997, 22:130-131, 134-138
21. Gerard GF, Shandilya H, Qiu P, Shi Y, Lo J. Genetic variance detection using Surveyor nuclease. Genetic Variance Detection: Technologies for Pharmacogenomics. Edited by Hecker KH. Eagleville PA, DNA Press, LLC, 2006, pp 95-129
22. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R: Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003, 35:146-150
23. Ronaghi M: Pyrosequencing for SNP genotyping. Methods Mol Biol 2003, 212:189-195
24. Huang ZH, Li LH, Hua D: Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 2006, 243:64-70
25. Yamada T, Nakamori S, OhzatoH, Oshima S, Aoki T, Higaki N, Sugimoto K, Akagi K, Fujiwara Y, Nishisho I, Sakon M, Gotoh M, Monden M: Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998, 4:1527-1532
26. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D: Microsatellite alterations in plasma DNA of head and neckcancer patients. Nat Med 1996, 2:1035-1037
27. Fleischhacker M, Schmidt B: Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007, 1775:181-232
28. Chiu RW, Poon LL, Lau TK, Leung TN, Wong EM, Lo YM: Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem 2001, 47:1607-1613
29. Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM: Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002, 48:421-427
30. Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K: Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 2003, 49:1028-1029
31. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665
32. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM: Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999, 64:218-224
33. de Kok JB, Hendriks JC, van Solinge WW, Willems HL, Mensink EJ, Swinkels DW: Use of real-time quantitative PCR to compare DNAisolation methods. Clin Chem 1998, 44:2201-2204
34. Stemmer C, Beau-Faller M, Pencreac'h E, Guerin E, Schneider A, Jaqmin D, Quoix E, Gaub MP, Oudet P: Use of magnetic beads for plasma cellfree DNA extraction: toward automation of plasma DNA analysis for molecular diagnostics. Clin Chem 2003, 49:1953-1955
35. Schmidt B, Weickmann S, Witt C, Fleischhacker M: Improved method for isolating cell-free DNA. Clin Chem 2005, 51:1561-1563
36. Board RE, Williams VS, Knight L, Shaw J, Greystoke A, Ranson M, Dive C, Blackhall FH, Hughes A: Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci 2008, 1137:98-107
37. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, Dunning A, Garte S, Matullo G, Overvad K, Tjonneland A, Clavel-Chapelon F, Boffetta P, Boeing H, Trichopoulou A, Palli D, Krogh V, Tumino R, Panico S, Bueno-de-Mesquita HB, Peeters PH, Lund E, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Berglund G, Hallmans G, Day NE, Key TJ, Veglia F, Peluso M, Norat T, Saracci R, Kaaks R, Riboli E, Vineis P: Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer 2004, 111:746-749
38. Chan KC, Yeung SW, Lui WB, Rainer TH, Lo YM: Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem 2005, 51:781-784
39. Swinkels DW, Wiegerinck E, Steegers EA, de Kok JB: Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin Chem 2003, 49:525-526
40. Le Calvez F, Ahman A, Tonisson N, Lambert J, Temam S, Brennan P, Zaridze DG, Metspalu A, Hainaut P: Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: comparison with denaturing HPLC and direct sequencing. Clin Chem 2005, 51:1284-1287
41. Jenkins GJ, Doak SH, Griffiths AP, Tofazzal N, Shah V, Baxter JN, Parry JM: Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology. Br J Cancer 2003, 88:1271-1276
42. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999, 59:67-70
43. Goessl C, Krause H, Müller M, Heicappell R, Schrader M, Sachsinger J, Miller K: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000, 60:5941-5945
44. Wong IH, Lo YM, Lai PB, Johnson PJ: Relationship of p16 methylation status and serum alpha-fetoprotein concentration in hepatocellular carcinoma patients. Clin Chem 2000, 46:1420-1422
45. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD: Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001, 61:900-902
46. Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH, Laurent-Puig P: Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002, 100:542-548
47. Usadel H, Brabender J, Danenberg KD, Jerónimo C, Harden S, Engles J, Danenberg PV, Yang S, Sidransky D: Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002, 62:371-375
48. Domínguez G, Carballido J, Silva J, Silva JM, García JM, Menéndez J, Provencio M, España P, Bonilla F: p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002, 8:980-985
49. Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S, Nakao A: Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 2003, 105:491-493